Skip to main content

Regulatory and Washington

  • Coalition of consumer groups opposes ESI-Medco merger

    WASHINGTON — A coalition of consumer groups on Tuesday joined its collective voice to the number of constituents opposing the Express Scripts-Medco merger in a letter to the Federal Trade Commission, according to a report filed by Reuters.

  • Sens. Conrad, Snowe raise bipartisan concerns over draft lists of Medicaid drug FULs

    ALEXANDRIA, Va. — In a bipartisan effort, Sens. Kent Conrad, D-N.D., and Olympia Snowe, R-Maine, along with 12 of their colleagues, have expressed concerns with draft Federal Upper Limits lists for Medicaid generic drug reimbursement that recently have been published by the Centers for Medicare and Medicaid Services.

    The National Association of Chain Drug Stores and National Community Pharmacists Association commended the Senators for the effort.

  • Mylan seeks approval for generic diabetes drug

    PITTSBURGH — Generic drug maker Mylan is challenging the patent on a drug used to treat diabetes, the company said Monday.

    Mylan said that it was sued by Takeda Pharmaceutical, Watson Pharmaceuticals and Andrx Labs in the U.S. District Court for the Southern District of New York in response to Mylan's filing a regulatory approval application with the Food and Drug Administration for a generic version of Actoplus Met XR (pioglitazone hydrochloride and metformin hydrochloride) extended-release tablets in the 15-mg/1,000-mg and 30-mg/1,000-mg strengths.

  • American Diabetes Association names 2012 board members

    ALEXANDRIA, Va. — The American Diabetes Association has announced its officers and board of directors for 2012.

    This year's board includes:

    • Board chairman L. Hunter Limbaugh, who serves as southeastern counsel of the Wine Institute in Columbia, S.C.;

    • Healthcare and education president Geralyn Spollett, who is the associate director of the Yale Diabetes Center and adult nurse practitioner, endocrine at Yale University in New Haven, Conn.;

  • Endo addresses possible short-term supply of Opana ER, other drugs

    CHADDS FORD, Pa. — Endo Pharmaceuticals announced a short-term supply constraint of analgesic products, including Opana ER, due to the temporary shutdown of a manufacturing facility operated by Novartis Consumer Health.

  • Novartis Consumer Health issues voluntary recall of certain OTCs sold in the United States

    BASEL, Switzerland — Following the recent voluntary suspension of operations and shipments from its Lincoln, Neb.-based facility, Novartis Consumer Health announced a voluntary recall of some of its over-the-counter products sold in the United States.

    The company said it is voluntarily recalling all lots of select bottle packaging configurations from retailers of Excedrin and NoDoz products with expiration dates of Dec. 20, 2014 or earlier, in addition to Bufferin and Gas-X Prevention products with expiration dates of Dec. 20, 2013 or earlier.

  • Achillion receives fast-track designation for hepatitis C drug

    NEW HAVEN, Conn. — The Food and Drug Administration has granted fast-track designation to a drug currently under development by Achillion Pharmaceuticals for hepatitis C, the company said.

  • Report: N.Y. senator proposes tougher penalties for pharmacy crime

    NEW YORK — A senator from New York is proposing new regulations that would protect pharmacies from robberies, according to published reports.

    The Associated Press reported that Sen. Charles Schumer, D-N.Y., proposed stronger penalties and better security measures so that pharmacies could protect their drugs, following a pharmacy robbery on Long Island that resulted in the death of an off-duty federal agent.

X
This ad will auto-close in 10 seconds